Acasti Pharma Income After Taxes 2014-2024 | GRCE
Acasti Pharma income after taxes from 2014 to 2024. Income after taxes can be defined as earnings or losses after income tax expense but before minority interest, extraordinary items, discontinued operations, preferred dividends and accounting changes have been accounted for.
Acasti Pharma Annual Income After Taxes
(Millions of US $) |
| 2024 |
$-13 |
| 2023 |
$-42 |
| 2022 |
$-10 |
| 2021 |
$-20 |
| 2020 |
$-26 |
| 2019 |
$-39 |
| 2018 |
$-17 |
| 2017 |
$-8 |
| 2016 |
$-5 |
| 2015 |
$-5 |
| 2015 |
$ |
| 2014 |
$-11 |
| 2014 |
$ |
| 2013 |
$-7 |
| 2013 |
$ |
Acasti Pharma Quarterly Income After Taxes
(Millions of US $) |
| 2024-06-30 |
$-3 |
| 2024-03-31 |
$-3 |
| 2023-12-31 |
$-2 |
| 2023-09-30 |
$-3 |
| 2023-06-30 |
$-4 |
| 2023-03-31 |
$-29 |
| 2022-12-31 |
$-4 |
| 2022-09-30 |
$-5 |
| 2022-06-30 |
$-5 |
| 2022-03-31 |
$-4 |
| 2021-12-31 |
$-4 |
| 2021-09-30 |
$1 |
| 2021-06-30 |
$-3 |
| 2021-03-31 |
$-6 |
| 2020-12-31 |
$-3 |
| 2020-09-30 |
$-6 |
| 2020-06-30 |
$-5 |
| 2020-03-31 |
$17 |
| 2019-12-31 |
$-12 |
| 2019-09-30 |
$-21 |
| 2019-06-30 |
$-9 |
| 2019-03-31 |
$-13 |
| 2018-12-31 |
$-3 |
| 2018-09-30 |
$-17 |
| 2018-06-30 |
$-6 |
| 2018-03-31 |
$-6 |
| 2017-12-31 |
$-5 |
| 2017-09-30 |
$-4 |
| 2017-06-30 |
$-2 |
| 2017-02-28 |
$-2 |
| 2016-11-30 |
$-2 |
| 2016-08-31 |
$-2 |
| 2016-05-31 |
$-2 |
| 2016-03-31 |
$-2 |
| 2016-02-29 |
|
| 2015-12-31 |
$-2 |
| 2015-09-30 |
$-1 |
| 2015-06-30 |
$-1 |
| 2015-03-31 |
$0 |
| 2014-12-31 |
$3 |
| 2014-09-30 |
$-3 |
| 2014-06-30 |
$1 |
| 2014-03-31 |
$0 |
| 2014-02-28 |
|
| 2013-12-31 |
$-4 |
| 2013-09-30 |
$-3 |
| 2013-06-30 |
$-2 |
| 2013-03-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-GENERIC DRG |
$0.033B |
$0.000B |
|
Acasti Pharma Inc. is a biopharmaceutical company. It is focused on research, development and commercialization of krill oil based forms of omega-3 phospholipid therapies. CaPre (R), Acasti's only prescription drug candidate, is being developed to help prevent and treat hypertriglyceridemia. ONEMIA (R) is a medical food and currently Acasti's only commercialized product. Acasti Pharma Inc. is headquartered in Laval, Canada.
|
